PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Intellia Therapeutics, Inc. (NTLA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45826J1051

CUSIP

45826J105

Sector

Healthcare

IPO Date

May 6, 2016

Highlights

Market Cap

$1.70B

EPS (TTM)

-$5.45

PEG Ratio

-0.10

Total Revenue (TTM)

$43.09M

Gross Profit (TTM)

$35.51M

EBITDA (TTM)

-$521.07M

Year Range

$13.95 - $34.87

Target Price

$59.12

Short %

18.07%

Short Ratio

6.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
NTLA vs. CRSP NTLA vs. AAPL NTLA vs. FVRR NTLA vs. SCHD NTLA vs. BEAM NTLA vs. GOOGL NTLA vs. VGT NTLA vs. PRME NTLA vs. BMY NTLA vs. SE
Popular comparisons:
NTLA vs. CRSP NTLA vs. AAPL NTLA vs. FVRR NTLA vs. SCHD NTLA vs. BEAM NTLA vs. GOOGL NTLA vs. VGT NTLA vs. PRME NTLA vs. BMY NTLA vs. SE

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Intellia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-45.86%
11.03%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Intellia Therapeutics, Inc. had a return of -54.03% year-to-date (YTD) and -50.16% in the last 12 months.


NTLA

YTD

-54.03%

1M

-33.52%

6M

-45.87%

1Y

-50.16%

5Y (annualized)

-1.31%

10Y (annualized)

N/A

^GSPC (Benchmark)

YTD

23.56%

1M

0.49%

6M

11.03%

1Y

30.56%

5Y (annualized)

13.70%

10Y (annualized)

11.10%

Monthly Returns

The table below presents the monthly returns of NTLA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-21.88%34.84%-14.35%-22.21%-0.09%4.68%17.11%-14.38%-8.42%-30.80%-54.03%
202321.64%-5.35%-7.22%1.29%-1.30%9.45%3.80%-11.46%-15.64%-20.78%18.28%2.90%-12.61%
2022-20.02%4.53%-26.48%-32.53%-5.89%12.18%25.12%-7.26%-6.83%-5.68%-2.50%-32.20%-70.49%
202115.11%-3.45%32.74%-4.34%-2.38%116.05%-12.39%13.17%-16.43%-0.87%-13.51%2.81%117.35%
2020-18.81%12.09%-8.39%10.14%29.99%20.05%-15.27%21.17%-7.88%20.42%64.04%38.53%270.82%
20193.59%7.71%12.15%-9.95%-9.75%17.94%10.57%-21.60%-5.92%-6.48%38.81%-15.35%7.47%
201833.71%1.56%-19.20%-5.07%35.36%0.96%-2.70%16.19%-7.47%-40.67%5.48%-23.79%-28.98%
2017-1.45%10.53%-1.33%3.41%-21.35%39.62%5.25%24.88%18.16%25.23%-27.63%-14.65%46.61%
201633.80%-27.80%-11.38%2.80%-12.49%-19.04%14.30%-16.76%-40.68%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NTLA is 10, indicating that it is in the bottom 10% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of NTLA is 1010
Combined Rank
The Sharpe Ratio Rank of NTLA is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of NTLA is 1111
Sortino Ratio Rank
The Omega Ratio Rank of NTLA is 1313
Omega Ratio Rank
The Calmar Ratio Rank of NTLA is 1616
Calmar Ratio Rank
The Martin Ratio Rank of NTLA is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for NTLA, currently valued at -0.74, compared to the broader market-4.00-2.000.002.004.00-0.742.51
The chart of Sortino ratio for NTLA, currently valued at -0.93, compared to the broader market-4.00-2.000.002.004.00-0.933.36
The chart of Omega ratio for NTLA, currently valued at 0.89, compared to the broader market0.501.001.502.000.891.47
The chart of Calmar ratio for NTLA, currently valued at -0.50, compared to the broader market0.002.004.006.00-0.503.62
The chart of Martin ratio for NTLA, currently valued at -1.62, compared to the broader market0.0010.0020.0030.00-1.6216.12
NTLA
^GSPC

The current Intellia Therapeutics, Inc. Sharpe ratio is -0.74. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Intellia Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.74
2.51
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Intellia Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-92.07%
-1.80%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Intellia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Intellia Therapeutics, Inc. was 92.10%, occurring on Nov 15, 2024. The portfolio has not yet recovered.

The current Intellia Therapeutics, Inc. drawdown is 92.07%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.1%Sep 7, 2021805Nov 15, 2024
-72.99%Mar 12, 2018507Mar 16, 2020178Nov 25, 2020685
-61.52%Jun 1, 2016251May 30, 201788Oct 3, 2017339
-44.32%Jan 20, 202133Mar 8, 202134Apr 26, 202167
-44.12%Nov 1, 201731Dec 14, 201756Mar 8, 201887

Volatility

Volatility Chart

The current Intellia Therapeutics, Inc. volatility is 29.12%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%JuneJulyAugustSeptemberOctoberNovember
29.12%
4.06%
NTLA (Intellia Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Intellia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Intellia Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items